Reports from the Field: Once-daily drug fights HIV.

Reports from the Field: Once-daily drug fights HIV

French researchers presented one-year results of a pilot study indicating that a once-a-day HAART (highly active antiretroviral therapy) regimen combining emtricitabine, didanosine, and efavirenz as a first-line therapy in treatment-naive HIV-infected patients was well-tolerated and effective.

Speaking at the 38th Annual Meeting of the Infectious Disease Society of America in New Orleans, researchers reported that at 48 weeks, 95% of patients on the regimen had a viral load below 400 copies/mL.

The results showed that the once-daily HAART regimen containing Coviracil (emtricitabine) was generally …